HbA1c-Driven Glycohypoxia as a Causal Axis Linking Hyperglycemia to Cancer in Type 2 Diabetes

Background: Type 2 diabetes mellitus (T2DM) increases cancer risk across multiple organs, yet mechanisms beyond insulin excess and adiposity remain unresolved. We propose glycohypoxia HbA1c-driven hemoglobin glycation that left-shifts the oxyhemoglobin curve and impairs tissue oxygen unloading as a pseudohypoxic trigger that stabilizes HIF-1α, promotes Warburg metabolism, amplifies ROS–RAGE–NF-κB signaling, and seeds oncogenesis. Methods: A PRISMA-guided meta-regression of 14 cohorts (>500,000 individuals; 5–36 years follow-up) synthesized adjusted hazard ratios (HRs) per 1% HbA1c using random-effects models (metafor). Cumulative glycemic load (AUC-HbA1c >7%) was computed trapezoidally and analyzed in time-varying Cox models. We assessed heterogeneity (I²), dose–response non-linearity (splines), and bias (Newcastle–Ottawa, Egger’s), and integrated tissue-specific vulnerabilities from 2023–2025 mechanistic literature. Results: Each 1% HbA1c increase elevated cancer hazards by 1.25 (pancreas), 1.22 (liver), 1.19 (endometrium), 1.18 (kidney), 1.16 (colorectum), and 1.12 (breast) (all CIs excluding 1.0; I² = 48–62%). AUC-HbA1c was a stronger amplifier: each +1 %×year raised risk 18–28%, with pancreatic and hepatic sites showing the steepest gradients. Individuals accumulating >120 %×years had ~1.9× higher overall risk versus <60. Increasing slopes by +0.1% per quarter raised overall hazards ~20%, independent of BMI, smoking, or diabetes duration. Risks doubled after >10 years of diabetes, and vulnerability scores correlated tightly with per-cancer slopes (r = 0.92). Conclusions: Glycohypoxia quantifies a coherent metabolic pathway linking chronic hyperglycemia to cancer development in T2DM. Maintaining HbA1c <7% and exploring hypoxia-modulating therapies may prevent 20–30% of attributable cancers. These findings establish cumulative glycemic exposure as an actionable biomarker of “glycemic memory” and a foundation for precision oncoprevention.